Savara SVRA
NASDAQ SVRA
$5.37 +0.00 (+0.00%)
As of: Sep 4, 2026 · 3:59 PM EDT

Savara (SVRA) Other Non Operating Income (2010 - 2026)

Savara (SVRA) posted quarterly Other Non Operating Income of -$216000.0 for Q1 2026, down 460.0% year-over-year from $60000.0 in Q1 2025, and down 118.26% quarter-over-quarter from $1.2 million in Q4 2025.

Analysis

Savara (SVRA) Other Non Operating Income (2010 - 2026) Analysis & Trends

Savara (SVRA) has reported Other Non Operating Income for 17 consecutive years, with -$216000.0 the latest figure, recorded in Q1 2026.

  • In Q1 2026, Other Non Operating Income fell 460.0% year-over-year to -$216000.0; the TTM figure through Mar 2026 stood at $2.2 million (down 79.69% YoY), while the FY2025 annual figure was $4.7 million, down 35.61% from the prior year.
  • Other Non Operating Income retreated to -$216000.0 in Q1 2026 per SVRA's latest filing, from $1.2 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $7.5 million in Q4 2024 and bottomed at -$254000.0 in Q1 2022.
  • Historically, Other Non Operating Income has averaged $916941.2 across 5 years, with a median of $60000.0 in 2025.
  • Annual changes were most pronounced in 2024 — Other Non Operating Income soared 210800.0% — and 2026, when it plunged 460.0%.
  • Savara's Other Non Operating Income stood at -$40000.0 in 2022, then jumped by 3927.5% to $1.5 million in 2023, then surged by 388.63% to $7.5 million in 2024, then slumped by 84.19% to $1.2 million in 2025, then slumped by 118.26% to -$216000.0 in 2026.
  • Business Quant data shows SVRA's Other Non Operating Income at -$216000.0 in Q1 2026, $1.2 million in Q4 2025, and $146000.0 in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Savara 1.36 Bn 1.36 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 737,000.00
Mar 31, 2026 1.71 Mn
Dec 31, 2025 1.18 Mn
Sep 30, 2025 694,000.00
Jun 30, 2025 1.04 Mn
Mar 31, 2025 1.80 Mn
Dec 31, 2024 2.13 Mn
Sep 30, 2024 2.11 Mn
Jun 30, 2024 947,000.00
Mar 31, 2024 2.13 Mn
Dec 31, 2023 1.53 Mn
Sep 30, 2023 1.45 Mn
Jun 30, 2023 778,000.00
Mar 31, 2023 1.56 Mn
Dec 31, 2022 575,000.00
Sep 30, 2022 149,000.00
Jun 30, 2022 219,000.00
Mar 31, 2022 -254,000.00
Dec 31, 2021 -671,000.00
Sep 30, 2021 -574,000.00